D C Blakey

1.4k citations

38 papers · 1.1k indexed · h-index 17

Impact in

Biotechnology top 2%
- Transgenic Plants and Applications
- Cancer Research and Treatments
Radiology, Nuclear Medicine and Imaging top 5%
- Monoclonal and Polyclonal Antibodies Research

Papers in

Biotechnology 14
- Cancer Research and Treatments 8
- Transgenic Plants and Applications 5
Radiology, Nuclear Medicine and Imaging 17
- Monoclonal and Polyclonal Antibodies Research 15
- Radiopharmaceutical Chemistry and Applications 4

Co-authors: P E Thorpe P.P. Knowles G Watson David R. Newell A N Brown Philip M. Wallace Caroline J. Springer Robert I. Dowell
Journals: British Journal of Cancer (7 papers)European Journal of Cancer (3 papers)Bone Marrow Transplantation (2 papers)Cytotherapy (2 papers)JNCI Journal of the National Cancer Institute (1 paper)
Partner nations: United Kingdom Australia United States

In The Last Decade

D C Blakey

37 papers receiving 1.1k citations

Peers

Countries citing papers authored by D C Blakey

Since Specialization

Citations

This map shows the geographic impact of D C Blakey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D C Blakey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D C Blakey more than expected).

Fields of papers citing papers by D C Blakey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D C Blakey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D C Blakey. The network helps show where D C Blakey may publish in the future.

Co-authorship network

The 25 scholars most cited alongside D C Blakey, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with D C Blakey Line = papers co-authored together D C Blakey links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Identification of novel vascular targets in lung cancer British Journal of Cancer ·Xiaodong Zhuang, John Herbert, Jung Keun, James Bradford, Alice Turner, В. Макареня, David Thickett, Abraham Grunwald, D C Blakey, Simon T. Barry, Darren A.E. Cross, Roy Bicknell	2014	23
2	A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo Oncogene ·Catherine A. Eberlein, Jane Kendrew, Karen McDaid, Cui Yanr, Abhishek Kumar, Vivien N. Jacobs, Sarah J. Ross, Claire Rooney, Neil R. Smith, Julie L. Rinkenberger, Alex Cao, Caifeng Chen, John F. Marshall, Hazel M. Weir, Vahe Bedian, D C Blakey, Ian N. Foltz, Simon T. Barry	2012	74
3	Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma British Journal of Cancer ·Marcel H.A.M. Fens, Kathryn J. Hill, Jean‐Pierre J. Issa, Sue Ashton, F. Russell Westwood, D C Blakey, G. Storm, Anderson J. Ryan, Raymond M. Schiffelers	2008	24
4	Changes in practice of breast cancer radiotherapy 1998–2002: An Australasian survey Australasian Radiology ·V. Dornberger, Andrew D. Mammen, Alison Evans, Karen Luxford, D C Blakey, Geoff P. Delaney, A. Rodger	2005	10
5	Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging British Journal of Cancer ·Simon P. Robinson, Dominick J. O. McIntyre, D. Checkley, Jean Tessier, Franklyn A. Howe, John R. Griffiths, S. Ashton, Anderson J. Ryan, D C Blakey, John C. Waterton	2003	94
6	CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy Cytotherapy ·H. Miles Prince, Dominic Wall, Danny Rischin, Guy C. Toner, J.F. Seymour, D C Blakey, David N. Haylock, Paul J. Simmons, M. Wolf, E. Januszewicz, David Westerman, Gary Richardson, John D. Scarlett, Peter Briggs	2002	7
7	Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy Cytotherapy ·H. Miles Prince, John Bashford, Dominic Wall, Danny Rischin, Neil J O'Sullivan, Guy C. Toner, John F. Seymour, D C Blakey, David N. Haylock, Paul J. Simmons, Prudence A. Francis, M. Wolf, E. Januszewicz, Gary Richardson, John D. Scarlett, Peter Briggs	2002	6
8	Docetaxel effectively mobilizes peripheral blood CD34+ cells Bone Marrow Transplantation ·H. Miles Prince, Guy C. Toner, J.F. Seymour, D C Blakey, Robin Latham, Soponyai János, О.П. Петросян, Dominic Wall, Michael Quinn, Surender Juneja, M. Wolf, AJAY JAMWAL, Gary Richardson, John D. Scarlett, Peter Briggs, George Altemose, Danny Rischin	2000	13
9	Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT) British Journal of Cancer ·Noel R. Monks, Rushikesh Wagh, Nicola J. Curtin, D C Blakey, Lily C. Johnston, David R. Newell	2000	3
10	A versatile system for receptor-mediated gene delivery permits increased entry of DNA into target cells, enhanced delivery to the nucleus and elevated rates of transgene expression Gene Therapy ·Kerry D. Fisher, Karel Ulbrich, Vladimír Šubr, Christopher M. Ward, Vivien Mautner, D C Blakey, Detlef Englich	2000	85
11	Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study Bone Marrow Transplantation ·H. Miles Prince, Danny Rischin, Guy C. Toner, J.F. Seymour, D C Blakey, Robin Latham, Soponyai János, О.П. Петросян, Michael Quinn, George Altemose, Surender Juneja, M Wolf, AJAY JAMWAL, Gary Richardson, John D. Scarlett, Peter Briggs	2000	10
12	Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: Results of a phase I study Annals of Oncology ·H. Miles Prince, Michael Millward, Danny Rischin, D C Blakey, Prudence A. Francis, Robin Latham, Д А Махотин, Michael Quinn, Surender Juneja, M Wolf, E. Januszewicz, J.F. Seymour, George Altemose, A. H. Strickland, John Zalcberg, Gary Richardson, John D. Scarlett, Peter Briggs, Guy C. Toner	1999	16
13	Engineered human carboxypeptidase B enzymes that hydrolyse hippuryl-L- glutamic acid: reversed-polarity mutants Protein Engineering Design and Selection ·Michael D. Edge, Guiselle Godínez Mora, Brian L. Fisher, Imshik Lee, David Tonge, M Mischlisch, J. Helen Fitton, 이해진, Lily C. Johnston, Hussein A. Majali, D C Blakey, A.F.G. Slater	1998	25
14	Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs British Journal of Cancer ·D C Blakey, Hà Thị Bích Liên, G. Hobbach, OlofFlodmark, PJ Burke, SK Sharma, Springer Cj, Marie‐Laure Garidou‐Boof, Hiroyuki Ishizuka	1995	20
15	Optimization of Alkylating Agent Prodrugs Derived from Phenol and Aniline Mustards: A New Clinical Candidate Prodrug (ZD2767) for Antibody-Directed Enzyme Prodrug Therapy Journal of Medicinal Chemistry ·Caroline J. Springer, Robert I. Dowell, P. J. Burke, (unknown), 羽入辰郎, D C Blakey, RG Melton, Ion Niculescu‐Duvaz	1995	64
16	Antitumor effects of an antibody-carboxypeptidase g2 conjugate in combination with a benzoic acid mustard prodrug Cell Biophysics ·D C Blakey, B. Valcaccia, Lily C. Johnston, Johnny X. Li, Xuhaoran Bai, Caroline J. Springer, Philip J. Burke, Roger G. Melton, K. D. Bagshawe	1993	16
17	Drug Targeting with Monoclonal Antibodies: A review Acta Oncologica ·D C Blakey	1992	17
18	Treatment of Malignant Disease and Rheumatoid Arthritis Using Ricin A-chain Immunotoxins Scandinavian Journal of Rheumatology ·D C Blakey, P E Thorpe	1988	2
19	Factors responsible for the formation of different N-alkylated porphyrins in rat liver microsomal systems exposed to norethindrone. The role of 3 α-hydroxysteroid dehydrogenase Biochemical Journal ·Ian N.H. White, D C Blakey, Sharon Andrisin, Michael Jarman, H.‐R. SCHULTEN	1986	2
20	Purification of ricin A1, A2, and B chains and characterization of their toxicity. Journal of Biological Chemistry ·R J Fulton, D C Blakey, P.P. Knowles, J W Uhr, P E Thorpe, E S Vitetta	1986	91

About D C Blakey

D C Blakey is a scholar working on Biotechnology, Radiology, Nuclear Medicine and Imaging, Immunology, Oncology and Toxicology, having authored 38 papers that have together received 1.1k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (15 papers), Toxin Mechanisms and Immunotoxins (9 papers), Cancer Research and Treatments (8 papers), Transgenic Plants and Applications (5 papers), Glycosylation and Glycoproteins Research (4 papers), Radiopharmaceutical Chemistry and Applications (4 papers), Peptidase Inhibition and Analysis (4 papers) and Biochemical and Molecular Research (3 papers). The work is most often cited by research in Biotechnology (276 citations), Radiology, Nuclear Medicine and Imaging (385 citations), Immunology (322 citations), Oncology (272 citations) and Immunology and Allergy (55 citations). D C Blakey has collaborated with scholars based in United Kingdom, Australia and United States. Frequent co-authors include P E Thorpe, P.P. Knowles, G Watson, David R. Newell, A N Brown, Philip M. Wallace, Caroline J. Springer, Robert I. Dowell, E S Vitetta and J W Uhr. Their work appears in journals such as British Journal of Cancer, European Journal of Cancer, Bone Marrow Transplantation, Cytotherapy and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact